Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, incorporated in 2002, is headquartered in Cambridge, Massachusetts, United States. The company is a prominent entity within the biopharmaceutical sector, with its primary focus on the development of RNA interference (RNAi) therapeutics. These therapeutics are targeted towards the treatment of a wide spectrum of diseases, including rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Among its products, Alnylam Pharmaceuticals has several notable marketed products such as ONPATTRO (patisiran), which is used for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). Another significant product is GIVLAARI (givosiran), designed to treat acute hepatic porphyria (AHP). OXLUMO (lumasiran) is a treatment for primary hyperoxaluria type 1 (PH1) available for both pediatric and adult patients, and LEQVIO (inclisiran) serves patients with hypercholesterolemia or mixed dyslipidemia. With a global reach, Alnylam Pharmaceuticals has its products and services sold in several major markets including the United States, countries within the European Union, and other regions worldwide where their drugs have received approval for commercial use. (Powered by AI)